Pepgen receives u.s. fda orphan drug and rare pediatric disease designations for pgn-edo51 for the treatment of duchenne muscular dystrophy

Boston, march 13, 2024 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the u.s. food and drug administration (fda) granted both orphan drug and rare pediatric disease designations for pgn-edo51, an investigational therapeutic for duchenne muscular dystrophy (dmd) patients whose mutations are amenable to an exon 51 skipping approach. pepgen is evaluating pgn-edo51 for the treatment of dmd in the ongoing connect1 phase 2 trial, and expects to begin enrolling patients in the connect2 phase 2 trial later this year.
PEPG Ratings Summary
PEPG Quant Ranking